| Literature DB >> 28321337 |
Abstract
Oral diseases associated with systematic diseases as metabolic and vasculitic have been included in this paper. This will enhance our understanding of the salivary function in promoting healthy oral condition. The study investigates the effects of type I and type II diabetes mellitus in well-controlled diabetic patients, in addition to Behçet disease (BD) on saliva flow rate (SFR), pH, the decay, missing, and filled tooth (DMFT) index, glucose, and major earth-alkaline ions (Ca2+ and Mg2+) compared to healthy males and age-matched controls. Saliva samples were collected from 1403 male human subjects, distributed on 7 levels including 3 control groups, and analyzed. The symptoms and clinical observations were enrolled. A preprandial salivary glucose has illustrated statistically strong significant and positive correlations with HbA1c and blood glucose levels. TIDM saliva showed lower pH, SFR, and Ca2+ but higher Mg2+, caries risk, and poor metabolic control. These led to dysfunction of secretory capacity of salivary glands. TIIDM proved higher SFR, DMFT, and glucose than TIDM patients. DM oral calcium has decreased by age while magnesium sharply slopes at seniority. BD oral fluid is associated with lower glucose and minerals but noticeably with both higher pH and DMFT.Entities:
Year: 2017 PMID: 28321337 PMCID: PMC5339495 DOI: 10.1155/2017/9596202
Source DB: PubMed Journal: Biochem Res Int
Figure 1Correlation between preprandial salivary and serum glucose levels in DM study group (p < 0.001).
Figure 2Correlation between preprandial salivary glucose levels and glycated hemoglobin (HbA1c) percentages in the study group (p < 0.001).
pH, SFR, DMFT, glucose, and electrolytes of whole saliva from patients with TIDM, TIIDM, and Behçet disease compared with control groups.
| Level | pH | SFR (mL/min) | DMFT index | Glucose (mg/dL) | Ca2+ (mM) | Mg2+ (mM) |
|---|---|---|---|---|---|---|
| 1 | 7.10 ± 0.72 | 0.82 ± 0.24 | 0.99 ± 0.72 | 0.96 ± 0.31 | 1.84 ± 0.64 | 0.15 ± 0.02 |
| 2 | 7.03 ± 0.70 | 1.07 ± 0.39 | 4.25 ± 0.19 | 2.29 ± 0.72 | 2.20 ± 0.07 | 0.47 ± 0.05 |
| 3 | 7.22 ± 0.75 | 0.92 ± 0.31 | 4.68 ± 0.28 | 2.33 ± 1.31 | 1.97 ± 0.43 | 0.21 ± 0.03 |
| 4 | 6.14 ± 0.42 | 0.27 ± 0.12 | 5.46 ± 1.82 | 8.93 ± 4.47 | 1.48 ± 0.39 | 0.23 ± 0.03 |
| 5 | 6.62 ± 0.46 | 0.73 ± 0.26 | 8.38 ± 0.28 | 10.28 ± 5.26 | 1.16 ± 0.39 | 0.38 ± 0.07 |
| 6 | 5.92 ± 0.32 | 0.67 ± 0.21 | 14.18 ± 3.25 | 13.37 ± 6.97 | 0.28 ± 0.01 | 0.10 ± 0.02 |
| 7(1) | 7.80 ± 0.96 | 0.74 ± 0.29 | 10.16 ± 5.44 | 1.11 ± 0.42 | 0.18 ± 0.05 | 0.02 ± 0.00 |
Differences of distributions in the two groups (patient-control) are presented as critical values for Mann–Whitney U test in parentheses; level of significance: 5% (p = 0.05).
Streptococcus mutans (S. mutans) (74.6% in patients with active oral ulcers versus 25.4% in inactive ulcers; p = 0.008) in the whole saliva was remarkably associated with disease severity, oral ulcers, and DMFT. S. mutans is a major etiology factor for the development of dental caries and is a member of oral biofilm [27]. Furthermore, no significant difference was observed in the healing time of oral ulcers for active (7.8 ± 1.4 days) and inactive (7.5 ± 2.2 days) diseases.
Comparison of clinical variables in diabetic group versus controls.
| Medical state (level) | CAO(2) | GI(3) | PI(4) | HbA1c(5) |
|---|---|---|---|---|
| Control 1 (Level 1) | 5.17 ± 3.72 | 0.46 ± 0.12 | 0.41 ± 0.18 | 6.96 ± 2.03 |
| TIDM (Level 4) | 8.15 ± 4.59 | 0.74 ± 0.16 | 0.65 ± 0.26 | 8.92 ± 2.72 |
|
| 2.483 | 0.592 | 0.611 | 0.332 |
| Control 2 (Level 2) | 6.90 ± 4.73 | 0.62 ± 0.14 | 0.57 ± 0.22 | 7.20 ± 2.12 |
| TIIDM (Level 5) | 14.6 ± 8.16 | 1.38 ± 0.27 | 1.19 ± 0.46 | 9.25 ± 3.41 |
|
| 2.749 | 0.706 | 0.735 | 0.402 |
| Control 3 (Level 3) | 7.18 ± 4.01 | 0.67 ± 0.18 | 0.63 ± 0.30 | 7.33 ± 2.15 |
| TIIDM (Level 6) | 15.4 ± 8.37 | 1.76 ± 0.44 | 1.58 ± 0.83 | 10.0 ± 3.74 |
|
| 3.119 | 0.782 | 0.806 | 0.445 |
: mean ± standard deviation.
Statistical significance (p < 0.05).
(2)Method developed by Knutson [41].
(3)Method developed by Löe [42].
(4)Method developed by Silness & Löe [43].
(5)Method developed by Flückiger & Mortensen [26].
Observatory clinical signs and symptoms associated with Behçet's disease.
|
| Frequency (%) | ||
|---|---|---|---|
| Residual | Probability | ||
| Disease activity (patient) | −2.11 | 0.05 | |
|
|
|
|
|
| Uveitis | 0.70 | 0.51 | 72.8 |
|
|
|
|
|
| Spastic gait | 0.27 | 0.22 | 28.4 |
|
| − |
|
|
| Incontinence | −0.17 | 0.12 | 16.7 |
|
| − |
|
|
| Papillitis | −0.26 | 0.10 | 11.6 |
|
| − |
|
|
| Vitritis | −0.39 | 0.08 | 4.9 |
|
|
| ||
| Item-trait interaction | 0.22 | ||
χ 2: Chi-squared statistic.
Residual: standardized difference between the observed score and the expected score according to the model.
Person separation index: the estimate of the replicability of person placement that can be expected if the samples of persons are given another set of items measuring the same construct. Analogous to Cronbach's α, it is bounded by 0-1 range (i.e., >0.8 is very good).
Item-trait interaction identifies the degree of the overall fit of the measure to the model. It assesses the degree to which the measure is diverging from the model in a systematic way that is not accounted for by chance alone.
Periodontal test outcomes of Behçet disease patients.
| Investigation | Findings |
|---|---|
| Disease duration (yr) | 8.2 ± 5.9 |
| GI(6) | 2.9 ± 0.7 |
| Number of carious teeth | 2.7 ± 2.6 |
| Number of extracted teeth | 5.3 ± 5.5 |
| Oral ulcers (number/month)(7) | 4.6 ± 6.2 |
| PI(8) | 2.8 ± 0.8 |
| Sulcus bleeding index (SBI)(9) | 3.1 ± 1.0 |
(6)Method developed by Löe [42].
(7)CI = 8.3 ± 1.7; PS = 60.7 ± 24.5.
(8)Method developed by Silness & Löe [43].
(9)Method developed by Mühlemann & Son [61].
Comparison of body mass index and biochemical and rheological parameters for inactive and active Behçet disease patients (n = 3).
| Variable | Inactive patients ( | Active patients ( |
|
|---|---|---|---|
| Body mass index (BMI) (kg/m2) | 22.8 ± 3.13 | 25.4 ± 3.52 | 0.609 |
|
|
|
|
|
| Plasma viscosity (PV) (cP) | 1.18 ± 0.05 | 1.29 ± 0.10 | 0.001 |
|
|
|
|
|
|
| |||
| Blood viscosity corrected hematocrit, 230 s−1 (BVc230 s−1) (cP) | 4.35 ± 0.29 | 5.04 ± 0.43 | 0.008 |
|
|
|
|
|
| Mean corpuscular volume (MCV) (femtoliters/cell (fL)) | 90.38 ± 4.74 | 88.27 ± 5.16 | 0.311 |
|
|
|
|
|
| Mean corpuscular hemoglobin concentration (MCHC) (%) | 34.89 ± 0.91 | 34.22 ± 1.20 | 0.157 |
|
|
|
|
|
| Leucocytes (Leu × 109/L) | 6.53 ± 1.08 | 7.80 ± 2.95 | 0.095 |
|
|
|
|
|
| Erythrocyte aggregation at 3 s−1 (EA1) | 6.63 ± 0.94 | 7.92 ± 1.20 | 0.003 |
|
|
|
|
|
| Total cholesterol (T-Chol) (mg/dL) | 211 ± 37 | 209 ± 39 | 0.611 |
|
|
|
|
|